These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. Jost WH; Friede M; Schnitker J Eur Rev Med Pharmacol Sci; 2014 Nov; 18(22):3349. PubMed ID: 25491607 [No Abstract] [Full Text] [Related]
25. [Rasagiline. A new monoamine oxidase b inhibitor for Parkinson treatment]. Oberpichler-Schwenk H Med Monatsschr Pharm; 2005 Jul; 28(7):224-7. PubMed ID: 16038119 [No Abstract] [Full Text] [Related]
27. Clinical trials of neuroprotection for Parkinson's disease. LeWitt PA Neurology; 2004 Oct; 63(7 Suppl 2):S23-31. PubMed ID: 15477583 [No Abstract] [Full Text] [Related]
28. [Monoamine oxidase inhibitors: prospects for the use in clinical practice]. Evtushenko SK; Lutskiĭ IS; Efimenko VN; Kazarian NE Zh Nevrol Psikhiatr Im S S Korsakova; 2002; 102(8):53-60. PubMed ID: 12233260 [No Abstract] [Full Text] [Related]
31. Monoamine oxidase inhibitors--is it time to up the TEMPO? Rascol O Lancet Neurol; 2003 Mar; 2(3):142-3. PubMed ID: 12849233 [No Abstract] [Full Text] [Related]
32. Neuroprotection by selegiline and other MAO inhibitors. Stern G J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613 [TBL] [Abstract][Full Text] [Related]
33. The evaluation of N-propargylamine-2-aminotetralin as an inhibitor of monoamine oxidase. Meiring L; Petzer JP; Legoabe LJ; Petzer A Bioorg Med Chem Lett; 2022 Jul; 67():128746. PubMed ID: 35447344 [TBL] [Abstract][Full Text] [Related]
34. Selegiline for Parkinson's disease. Calesnick B Am Fam Physician; 1990 Feb; 41(2):589-91. PubMed ID: 2105624 [TBL] [Abstract][Full Text] [Related]
35. New mechanisms of action of irreversible monoamine oxidase type B inhibitors. Li XM; Juorio AV; Paterson IA; Boulton AA J Psychiatry Neurosci; 1993 Jul; 18(4):199-200. PubMed ID: 8373757 [No Abstract] [Full Text] [Related]
36. Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression. Weinstock M; Poltyrev T; Bejar C; Youdim MB Psychopharmacology (Berl); 2002 Mar; 160(3):318-24. PubMed ID: 11889501 [TBL] [Abstract][Full Text] [Related]
37. Electropharmacograms of rasagiline, its metabolite aminoindan and selegiline in the freely moving rat. Dimpfel W; Hoffmann JA Neuropsychobiology; 2010; 62(4):213-20. PubMed ID: 20714170 [TBL] [Abstract][Full Text] [Related]
38. A perspective on adjunctive therapy for Parkinson disease with monoamine oxidase-B inhibition. LeWitt PA Clin Neuropharmacol; 2007; 30(5):305-7. PubMed ID: 17909310 [No Abstract] [Full Text] [Related]
39. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Fernandez HH; Chen JJ Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750 [TBL] [Abstract][Full Text] [Related]
40. Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease. Jansen Steur EN; Ballering LA Adv Neurol; 1999; 80():505-8. PubMed ID: 10410764 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]